Site of Care Infusion Drugs
Blue Cross Blue Shield of Wyoming’s site of care program requires certain services that may have been received in a hospital setting to now only be authorized in the most cost-effective setting, such as an infusion center, provider’s office, or via home health including the use of subcutaneous injectables. If needed, BCBSWY will assist members with finding an appropriate site for care. All medications under this program require Prior Authorization.
If administration of the list of drugs below are not approved to be performed in an inpatient or outpatient hospital setting members can receive infusion treatments at facilities such as free-standing infusion center, doctor’s office, pharmacy, or via home health. Failure to receive the service in an approved location could result in the denial of claims. The financial responsibility of the denied amount will be the members responsibility.
Please be advised that while the medication may have been approved as medically appropriate, the member’s benefits may require this service be provided in specific locations.
If needed, our Site of Care Team can assist members with finding an appropriate site for care. Our team is available Monday-Friday, 8:00 am-5:00 pm, by calling 307-823-6095 to assist you.
Asceniv
Bivigram
Cutaquig
Cuvitru
Flebogamma
Gamastan
Gammagard
Gammaplex
Gamunex
Hizentra
HyQvia
Octagam
Panzyga
Privigen
Vivaglobin
Xembify
Preferred Product Program
Some members may be required to receive preferred medications, including biosimilar medications for coverage under their health plan. Preferred medications offer the same safety and effectiveness but at a lower cost, keeping health care costs lower.
Many preferred medications below are called biosimilar medications which are made from livin organisms such as animal or plant cells, bacteria, or yeast, rather than being chemically synthesized like similar medications.
| Drug Class | Preferred Product (2027 Changes in Bold) |
| Bevacizumab | 2026: Mvasi & Zirabev 2027: Mvasi, Zirabev, Vegzlema |
| Rituximab | 2026: Ruxience, Truxima, Riabni 2027: Ruxience, Truxima, Riabni |
| Infliximab | 2026: Avsola, Inflectra 2027: Avsola, Inflectra, Renflexis |
| Viscosupplements | 2026: Durolane, Gelsyn-3, Supartz, Gel-One, Visco-3 2027: Durolane, Gel-One (Note: Gelsyn-3, Supartz, and Visco-3 are no longer preferred medications) |
| Immune Globulins IV | 2026: Octagam, Gemmaked, Gamunix-C, Gammargard, Privigen 2027: Octagam, Gemmaked, Gamunix-C, Gammargard, Privigen |
| Immune Globulins SC | 2026: Hyqvia, Hizentra, Xembify, Cutaquig 2027: No preferred medication. Any medication in this category may be used for members. |
| Ustekinumab | 2026: Selarsdi, Yesintek, Steqeyma 2027: Selarsdi, Yesintek (Note: Steqeyma is no longer a preferred medication) |
| Infused Iron | 2026: Feraheme, Ferrlecit, INFed, Venofer 2027: Feraheme, Ferrlecit, INFed, Venofer |
| Trastuzumab | 2027: Kanjinti, Ogivri |
| Filgrastim | 2027: Zivestym, Zerxio |
| Pegfilgastim | 2027: Fulphila, Udenyca |
| Lupus | 2027: Venlysta (IV), Saphnelo (SC) |
| Denosumab Biosimilars (Xgeva) | 2027: Biloprevda, Xtrenbo |
| Denosumab Biosimilars (Prolia) | 2027: Bildyos, Enoby |
| Injectable Asthma | 2027: Nucala, Fasenra |
| Ocular VEGF | 2027: Bevacizumab (Note: There is no prior authorization necessary for Ocular VEGF) |
Prior Authroization
Many of the preferred medications above require prior authorization. To review prior authorization requirements and submit an authorization go to Availity.com.
Effective Date of Preferred Products
We encourage all providers to provide the preferred products for our members starting January 1, 2027. Enforcement of the program will go into effect with new medication prior authorizations or upon authorization renewal. If you need help with a census of members who need to transition in 2027, please reach out to our CarePath team.
Exceptions
Member safety is our top priority. If you feel a member may need an exception due to a contraindication, please submit this documentation with your prior authorization. If you need assistance outside of the prior authorization process, please contact our CarePath medication team at 307-823-6095.
General Questions:
The CarePath medication team is available to members and providers. If you’re currently taking one of these medications or prescribing these medications and have questions or concerns, please call 307-823-6095.